IMP 701Alternative Names: ImmunTune IMP701 antagonist antibody - Prima Biomed; IMP701
Latest Information Update: 24 Aug 2015
At a glance
- Originator Immutep
- Developer CoStim Pharmaceuticals; Novartis
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CD223 antigen inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
- Preclinical Infections